Clinical Research Directory
Browse clinical research sites, groups, and studies.
Serum Level of IL-33 in Egyptian Psoriatic Patients
Sponsor: scientific_committee
Summary
This study aimed to compare the serum concentration levels of IL-33 in psoriatic patients undergoing treatment with two commonly prescribed immunosuppressive drugs, methotrexate and cyclosporine. Blood samples will be collected, Serum IL-33 concentrations will be measured using enzyme-linked immunosorbent assay (ELISA) techniques. Clinical assessments, including Psoriasis Area and Severity Index (PASI) scores, will be also recorded to evaluate disease severity and treatment efficacy.
Official title: Cyclosporine Mitigated the Augmented Serum Level of IL-33 in Egyptian Psoriatic Patients in Relation to Disease Severity
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
118
Start Date
2026-06-01
Completion Date
2027-03-01
Last Updated
2026-04-29
Healthy Volunteers
No
Conditions
Interventions
serum interleukin 33 measurement
Blood samples will be collected from participants under aseptic conditions. Serum will be separated and stored appropriately. Serum Interleukin-33 (IL-33) levels will be measured using enzyme-linked immunosorbent assay (ELISA) to evaluate its association with psoriasis.
PASI score
The Psoriasis Area and Severity Index (PASI) is the most widely utilized quantitative tool in clinical dermatology and pharmacological research for grading the severity of chronic plaque psoriasis. It provides a composite score based on the clinical manifestation of the disease across distinct anatomical regions